Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Lonza grants Genentech license

February 20, 2006 | A version of this story appeared in Volume 84, Issue 8

Lonza has issued Genentech a nonexclusive, global license to its glutamine synthetase gene expression system, a mammalian expression and vector amplification system that, according to the company, capitalizes on selection via glutamine metabolism and viral promoters. The initial research agreement allows Genentech to use the system for R&D, but it includes options for a multiproduct license for commercial purposes. Genentech also has the option to license Lonza's protein-free media system for both R&D and commercial purposes.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.